Pipeline Program

About MatriSys Bioscience

MatriSys Bioscience is a private, pre-revenue biotech company leveraging a proprietary discovery platform to develop topical live biotherapeutics from beneficial skin bacteria. Its lead program targets atopic dermatitis, with additional candidates for acne, Netherton syndrome, and other disorders, addressing a significant unmet need in dermatology. The company is led by a seasoned team with strong scientific roots in skin immunology and microbiome research from UCSD and extensive drug development experience. MatriSys aims to reduce reliance on steroids and immunosuppressants by restoring the natural skin microbiome.

About MatriSys Bioscience

MatriSys Bioscience is a private, pre-revenue biotech company leveraging a proprietary discovery platform to develop topical live biotherapeutics from beneficial skin bacteria. Its lead program targets atopic dermatitis, with additional candidates for acne, Netherton syndrome, and other disorders, addressing a significant unmet need in dermatology. The company is led by a seasoned team with strong scientific roots in skin immunology and microbiome research from UCSD and extensive drug development experience. MatriSys aims to reduce reliance on steroids and immunosuppressants by restoring the natural skin microbiome.

About Pristine Surgical

Pristine Surgical is a private, commercial-stage medical device company pioneering a 'Scopes as a Subscription' model for 4K single-use endoscopes. Its initial product, Summit™, is a single-use surgical arthroscope, supported by the Pristine Connect® cloud software for inventory management and data sharing. The company aims to disrupt the traditional reusable endoscope market by addressing high costs, maintenance burdens, and infection risks, with a pipeline targeting broader endoscopic applications like laparoscopy and flexible endoscopy. Backed by an experienced executive team and medical advisory board, Pristine is positioned to capitalize on the growing shift toward disposable medical devices.

About Pristine Surgical

Pristine Surgical is a private, commercial-stage medical device company pioneering a 'Scopes as a Subscription' model for 4K single-use endoscopes. Its initial product, Summit™, is a single-use surgical arthroscope, supported by the Pristine Connect® cloud software for inventory management and data sharing. The company aims to disrupt the traditional reusable endoscope market by addressing high costs, maintenance burdens, and infection risks, with a pipeline targeting broader endoscopic applications like laparoscopy and flexible endoscopy. Backed by an experienced executive team and medical advisory board, Pristine is positioned to capitalize on the growing shift toward disposable medical devices.

About Novilla Pharmaceuticals

Novilla Pharmaceuticals is a private, pre-revenue biotechnology company leveraging a proprietary AI-driven drug delivery platform to design localized therapeutics. Its lead candidate, NOV-1776, has recently completed human clinical trials, demonstrating a 212% increase in efficacy over standard of care with minimal systemic exposure and no gastrointestinal adverse events. The company is targeting multiple therapeutic areas including gout, general pain, and joint inflammation, with a seasoned leadership team combining deep expertise in neurology, pain therapeutics, chemistry, and AI.

About Novilla Pharmaceuticals

Novilla Pharmaceuticals is a private, pre-revenue biotechnology company leveraging a proprietary AI-driven drug delivery platform to design localized therapeutics. Its lead candidate, NOV-1776, has recently completed human clinical trials, demonstrating a 212% increase in efficacy over standard of care with minimal systemic exposure and no gastrointestinal adverse events. The company is targeting multiple therapeutic areas including gout, general pain, and joint inflammation, with a seasoned leadership team combining deep expertise in neurology, pain therapeutics, chemistry, and AI.

About Novilla Pharmaceuticals

Novilla Pharmaceuticals is a private, pre-revenue biotechnology company leveraging a proprietary AI-driven drug delivery platform to design localized therapeutics. Its lead candidate, NOV-1776, has recently completed human clinical trials, demonstrating a 212% increase in efficacy over standard of care with minimal systemic exposure and no gastrointestinal adverse events. The company is targeting multiple therapeutic areas including gout, general pain, and joint inflammation, with a seasoned leadership team combining deep expertise in neurology, pain therapeutics, chemistry, and AI.

About Novilla Pharmaceuticals

Novilla Pharmaceuticals is a private, pre-revenue biotechnology company leveraging a proprietary AI-driven drug delivery platform to design localized therapeutics. Its lead candidate, NOV-1776, has recently completed human clinical trials, demonstrating a 212% increase in efficacy over standard of care with minimal systemic exposure and no gastrointestinal adverse events. The company is targeting multiple therapeutic areas including gout, general pain, and joint inflammation, with a seasoned leadership team combining deep expertise in neurology, pain therapeutics, chemistry, and AI.

About Novilla Pharmaceuticals

Novilla Pharmaceuticals is a private, pre-revenue biotechnology company leveraging a proprietary AI-driven drug delivery platform to design localized therapeutics. Its lead candidate, NOV-1776, has recently completed human clinical trials, demonstrating a 212% increase in efficacy over standard of care with minimal systemic exposure and no gastrointestinal adverse events. The company is targeting multiple therapeutic areas including gout, general pain, and joint inflammation, with a seasoned leadership team combining deep expertise in neurology, pain therapeutics, chemistry, and AI.

About TenNor Therapeutics

A clinical-stage Chinese biotech developing novel multi-target conjugate molecules for bacterial infections and metabolic diseases.

About TenNor Therapeutics

A clinical-stage Chinese biotech developing novel multi-target conjugate molecules for bacterial infections and metabolic diseases.

About TenNor Therapeutics

A clinical-stage Chinese biotech developing novel multi-target conjugate molecules for bacterial infections and metabolic diseases.

Therapeutic Areas

Other Acne Vulgaris Drugs